Drugs / ALLO-ASC
ALLO-ASC
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01856140 | May 2013 → Jul 2016 | epicondylitis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02580617 | Nov 2015 → Dec 2023 | Crohn disease | Anterogen Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02384499 | Dec 2014 → Jun 2017 | — | Yonsei University | Completed | No outcome recorded |
| Phase 1 | NCT01440699 | Sep 2011 → Oct 2012 | Crohn disease | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03449082 | Mar 2018 → Jul 2019 | epicondylitis | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-ASC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02580617 ↗ |
| Known as | ALLO-ASCs | “allogeneic-adipose-derived mesenchymal stem cells (ALLO-ASCs)” PMID 26888731 ↗ Feb 2016 |
| Known as | Allogenic human adipose-derived stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01440699 ↗ |
| Modality | Cell therapy | “adipose-derived stem cells” NCT01440699 ↗ |
| Route | Other | “injected once along the fistula” NCT01440699 ↗ |